Stephen Kolb, MD
Neurology · Columbus, OHNPI 1477608388
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 45.1% of the total. Reporting peaked in 2019 at $21,131 and has fallen 97.0% since, to $641 in 2024.
Across 39 payments — averaging $1045.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$18K
- Biogen$8K
- Genentech, Inc.$6K
- Genentech USA, Inc.$5K
- F. Hoffmann-la Roche AG$2K
- Regeneron$641
- plus $219 from 1 others
Across 58 payments — averaging $5206.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$138K
- Novartis$105K
- Ionis Pharmaceuticals, Inc.$54K
- Leadiant Biosciences, Inc.$6K
What the payments were for
- Consulting fees$20,38450%
- Speaking & faculty fees$17,01442%
- Travel & lodging$2,1075%
- Food & beverage$1,0543%
- Education$2191%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 17 | $18,384 |
| Biogen | 7 | $8,340 |
| Genentech, Inc. | 7 | $5,906 |
| Genentech USA, Inc. | 2 | $5,248 |
| F. Hoffmann-la Roche AG | 1 | $2,040 |
| Regeneron | 1 | $641 |
| Alnylam Pharmaceuticals Inc. | 4 | $219 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$8,693
- Non-Covered Product$7,848
- SPINRAZA$5,360
- EVRYSDI$5,290
How this compares
$40,779 in reported general payments places this provider in the 85th percentile of 702 neurology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 16 | $27,744 |
| Riluzole | 61 | $17,923 |
| Baclofen | 22 | $626 |
| Amitriptyline Hcl | 15 | $305 |
Paid to pharmacies, not to this prescriber.
Other neurology in Columbus
- Kenneth MankowskiColumbus$1.4M
- Aaron BosterColumbus$1.2M
- Jacqueline NicholasColumbus$743K
- Geoffrey EubankColumbus$508K
- Jerry MendellColumbus$315K
- Andrew SmithColumbus$254K
- Douglas ScharreColumbus$191K
- Aristide MerolaColumbus$133K
- Miriam FreimerColumbus$105K
- Allison JordanColumbus$98K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.